VV-TZ · Research pen
Tirzepatide 40mg research pen
The Vivora Tirzepatide 40mg research pen is one pre-filled pen labelled 40mg, packed in its own sealed, batch-coded window box.
Dual receptor agonist: GIP and GLP‑1
- Label strength: 40mg
- Pens per box: 1
- In the box: 1 pre-filled research pen, a sealed window box and a printed batch code
- Price: £100 per box, with the UK delivery charge shown before payment
- Availability: checked live when this page loads, and again at checkout
- Batch report: published, see the lab-reports page
For laboratory research only. Not for human or animal consumption.
Compare the full range · Research pens and vials: what to compare · How to read a peptide lab report
Check packaging and published batch records · Research use policy · UK delivery
Key facts
Also known as LY3298176
| Compound | Tirzepatide (LY3298176) |
|---|---|
| Label strength | 40mg |
| Format | Pre-filled research pen, sealed window box |
| Pens per box | 1 |
| Price | £100 per box |
| Price per mg | £2.50 per mg (£100 ÷ 40mg) |
| UK delivery | £4.95 per order |
More about Tirzepatide
What LY3298176 is
LY3298176 is the research code for tirzepatide, a synthetic peptide with agonist activity at two receptors, GIP and GLP-1. Its 2018 discovery paper, from Eli Lilly and Company, describes a 39-amino-acid linear peptide joined through a linker to a C20 fatty diacid on the lysine at position 20. Positions 2 and 13 hold the non-coded amino acid Aib (alpha-aminoisobutyric acid), and the C-terminus is amidated.
A 2020 pharmacology study calls it an imbalanced and biased dual agonist. Imbalanced, because it engages the GIP receptor to a greater degree than the GLP-1 receptor; biased, because at the GLP-1 receptor it favours cAMP signalling over beta-arrestin recruitment. Retatrutide adds the glucagon receptor as a third target.
- Research code
- LY3298176
- CAS number
- 2023788-19-2
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813 g/mol
- Chain length
- 39 amino acids, amidated C-terminus
- Receptor targets
- GIP and GLP-1 receptors
- Class
- Dual receptor agonist peptide
- Development status
- Approved stage (phase 4), first approval 2022
Sources
- Coskun T et al. Mol Metab. 2018: research code, receptor targets and peptide structure
- Willard FS et al. JCI Insight. 2020: imbalanced and biased dual agonist
- PubChem CID 156588324: molecular formula, molecular weight and CAS number
- ChEMBL CHEMBL4297839: development phase and first approval year
Tirzepatide vs retatrutide
Easy to mix up: both are 39-residue synthetic peptides developed by Eli Lilly and Company, both carry a C20 fatty diacid, and Vivora sells each as a 40mg research pen. They are not two names for one compound. Tirzepatide is a dual agonist with no glucagon receptor target; retatrutide is a triple agonist that adds one. Their sequences differ too: tirzepatide's fatty diacid sits on lysine 20, retatrutide's on lysine 17.
| Receptor or feature | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes, engaged more than GLP-1 | Yes, more activity than at GLP-1 in vitro |
| Glucagon receptor | No | Yes |
| Research code | LY3298176 | LY3437943 |
| Discovery paper | Coskun et al., Mol Metab 2018 | Coskun et al., Cell Metab 2022 |
| Highest stage | Approved (phase 4) since 2022 | Phase 3 |
| Price per mg at Vivora | £2.50 | £4.00 |
Sources
- Coskun T et al. Cell Metab. 2022: retatrutide's three receptor targets and in vitro GIP receptor activity
- ChEMBL CHEMBL5095485: retatrutide's highest phase
- FDA GSRS, retatrutide: retatrutide's fatty diacid position
Regulatory status
Tirzepatide is no longer investigational. In the US it is classed as a prescription medicine: the FDA drug approvals database lists application NDA 215866 from Eli Lilly and Company as a new molecular entity, first approved on 13 May 2022. In the EU it is classed as an authorised medicine: the European Commission granted a centralised marketing authorisation, EU/1/22/1685, on 15 September 2022, following EMA procedure EMEA/H/C/005620.
Those approvals cover the licence holder's own authorised products. Vivora's Tirzepatide pen is not one of them: it is a laboratory research material, it is not a medicine, and it is supplied without dosing, preparation or administration guidance.
Sources
- FDA drug approvals database, NDA 215866: marketing status, applicant and original approval date
- EU Union Register, EU/1/22/1685: EU authorisation decision date and EMA procedure number
- ChEMBL CHEMBL4297839: phase 4, first approval 2022
What 40mg means
Vivora's Tirzepatide pen is labelled 40mg: the stated amount of tirzepatide in that one pen. Each box holds a single pen, so 40mg is also the box total.
At £100 per box the price is £2.50 per mg (£100 ÷ 40mg). Vivora's Retatrutide pen carries the same 40mg label amount at £4.00 per mg, so the two compare directly. For listings quoting mg per vial or per multi-container pack, work out the total per box first.
Buying from Vivora
UK delivery is £4.95 per order, shown before payment. Every pen is filled fresh for your order, and orders paid by 3pm, Monday to Thursday, are dispatched the same day. Pay by UK bank transfer after you place your order. Unopened boxes can be returned within 30 days of delivery for a full refund. Store sealed at 2 to 8°C. See delivery information, returns and refunds and our guide to research pens and vials.
Questions, answered.
How many mg are in a tirzepatide pen?
Vivora's Tirzepatide research pen is labelled 40mg, and each box holds that one pen, so a box also holds 40mg in total. Pen sizes differ between suppliers, so check the stated mg per container and how many containers come in a box.
How much is the Tirzepatide 40mg pen?
£100 per box, for one pre-filled 40mg research pen. That is £2.50 per mg of label strength. UK delivery is £4.95 per order, shown before payment.
Is tirzepatide a peptide?
Yes. It is a synthetic linear peptide of 39 amino acids, two of them the non-coded amino acid Aib, with a C20 fatty diacid attached through a linker to one lysine. PubChem records it as a single compound with the formula C225H348N48O68.
What is LY3298176?
The research code for tirzepatide, also written LY-3298176. Eli Lilly and Company used it in the 2018 discovery paper and in the first studies of the compound; tirzepatide is its non-proprietary name.
Is tirzepatide the same as retatrutide?
No. Tirzepatide (LY3298176) is a dual agonist at the GIP and GLP-1 receptors and reached approval in 2022. Retatrutide (LY3437943) is a separate, investigational molecule that also targets the glucagon receptor. Vivora sells each as its own 40mg pen; see Retatrutide.
Why is tirzepatide called a dual agonist?
Because one molecule activates two different receptors, the GIP receptor and the GLP-1 receptor. A 2020 study adds two qualifiers: imbalanced, as it engages the GIP receptor more than the GLP-1 receptor, and biased, as at the GLP-1 receptor it favours cAMP signalling over beta-arrestin recruitment.
Is Vivora's tirzepatide pen licensed?
No. It is a research material for laboratory use and is not a licensed medicine, nor the authorised product approved in the US and the EU. It is sold without dosing, preparation or administration guidance, to buyers aged 18 or over who confirm research use.